T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (1242)	7/4/2002 10:07:27 AM
From: scaram(o)uche	of 2243

Thanks, very much, for the answer. Given margins and the arguments re. compensation for development costs, I guess FDA -- particularly without head honcho -- might be justified for having high bars. Pharmaceutical margins are obscene, we all know that. We need the me-too Allegras of the world. We need fragmented markets. HMOs are despised, but they're a real effort to find some workable method in this world of obscene cost and profit. I trust that we'd all love to see the bar raised high enough such that ambulance chasers went poof, but there has to be some "in between". As long as man competes for space and resources, FDA must be an active partner for innovation. But high safety bars are good. Switching subjects, but running around the same theme..... pharma margins allowed the last generation of biotech IPOs to debut with dotcom-like equity structures. Insiders and VCs had 5X the traditional number of shares. We're paying the price now. As a result, many private companies are already reverse splitting. A flood will follow, as there is not yet concern with getting through any window (given that it isn't in sight). Things are getting fixed. Bandaids, in the larger scope of things.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next